Nuvustotug
Based on 1 Customer Validation
Nuvustotug (HFB301001) is an OX40 agonist monoclonal antibody with a KD of 2.86 ×10-7 M. Nuvustotug binds OX40 CRD1 without blocking OX40L, promoting receptor clustering and NF-κB signaling. Nuvustotug induces FcγRIIIa-mediated antibody-dependent cell-mediated cytotoxicity and FcγR-dependent depletion of OX40-high Tregs, promoting CD8+ T cell activation, proliferation, and effector release. Nuvustotug remodels the tumor immune microenvironment and induces long-lasting antitumor immune memory in various mouse cancer models. Nuvustotug can be used in cancer-related research.
For research use only. We do not sell to patients.
- Purity : 95.36%
- CAS No.: 2916519-49-6
- Molecular Weight:144.734 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFRSF4/OX40/CD134
In Vitro
Nuvustotug does not block OX40L-induced OX40 reporter gene activation[2].
Nuvustotug (2-10 nM; 12 h) induces stronger OX40 receptor clustering than its high-affinity variant in HEK293T-OX40-GFP cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293T-OX40-GFP cells
-
Concentration:2 nM and 10 nM
-
Incubation Time:12 h at 37°C
-
Result:Induced stronger OX40 clustering than the high-affinity variant at both 2 nM and 10 nM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:humanized OX40 mice on a C57BL/6J genetic background (female, 6-8 weeks old, approximately 1 × 106 MC38 cells were s.c. inoculated on both sides)[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; once every 3 days; 3 doses
-
Result:Delayed tumor growth in a subset of MC38-bearing humanized OX40 mice and defines a responder population with T/C < 40% and NOS2+ TAM polarization.
-
Animal Model:C57BL/6J (humanized OX40; female, 6-8 weeks, approximately 1 × 106 MC38 cells were s.c. inoculated on both sides)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 3 days; three doses
-
Result:Inhibited MC38 tumor growth and promotes intratumoral and tumor-draining lymph node CD8+ T-cell activation with Treg reduction.
-
Animal Model:C57BL/6J (humanized OX40; female; 6-8 weeks; were subcutaneously inoculated with 1×106 E.G7 cells)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 3 days; three doses; i.p. for ELISpot
-
Result:Inhibited E.G7 tumor growth and improved survival without body weight reduction.
ELISpot showed a greater number of tumor-specific IFN-γ-secreting splenocytes from E.G7-OVA tumor-bearing mice than from vehicle control mice.
-
Animal Model:C57BL/6J (humanized OX40; female; 6-8 weeks; were subcutaneously inoculated with 1×106 MC38 cells)[2]
-
Dosage:0.1 mg/kg, 1 mg/kg, and 10 mg/kg
-
Administration:i.p.; days 6, 9, and 12
-
Result:Produced dose-dependent tumor growth inhibition; the most pronounced tumor volume reduction occurred at 10 mg/kg.
The 10 mg/kg dose conferred a survival advantage.
-
Animal Model:C57BL/6J (wild-type and Fcgr3 knockout recipients; hOX40 mouse-derived Treg donors; female; 6-8 weeks; were subcutaneously inoculated with 1×106 MC38 cells)[2]
-
Dosage:5 mg/kg
-
Administration:i.p.; days 6, 9, 12, and 15
-
Result:Showed greater antitumor efficacy in MC38 tumors in WT than in Fcgr3 KO recipients after hOX40 Treg transfer.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized OX40/TNFRSF4 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78189) can bind Nuvustotug. The EC50 for this effect is 25.84 ng/mL. -
Flow cytometric analysis of 1X106 Jurkat cells labeling CD134 with Nuvustotug (HY-P991012, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2916519-49-6
-
Appearance Liquid
-
Molecular Weight 144.734 kDa
-
Color Colorless to light yellow
-
SMILES
[Nuvustotug]
-
Synonyms
HFB301001
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nuvustotug Related Classifications
HY-P991012 Related Classifications
Powered by Bioz